FN1 and neoplasm: The CREKA peptide can specifically bind to the fibrin-fibronectin complex upregulated in the extracellular matrix (ECM) of tumor tissue, thereby avoiding the distribution of MRI contrast agents in normal organs and tissues to improve the detection of micrometastases.